Loading...
Loading...
BEAM| Name | Value |
|---|---|
| Revenues | 17.2M |
| Cost of Revenue | 7.5M |
| Gross Profit | 9.7M |
| Operating Expense | 125.5M |
| Operating I/L | -108.3M |
| Other Income/Expense | 12.2M |
| Interest Income | 12.7M |
| Pretax | -96.1M |
| Income Tax Expense | -17.4M |
| Net Income/Loss | -96.1M |
Beam Therapeutics Inc. is a biotechnology company specializing in developing precision genetic medicines for serious diseases. The company's product pipeline includes BEAM-101 and BEAM-102 for treating sickle cell disease and beta thalassemia, BEAM-201 for relapsed/refractory T-cell acute lymphoblastic leukemia, and BEAM-301 for Glycogen Storage Disease Type Ia. Additionally, it focuses on therapies for alpha-1 antitrypsin deficiency, ocular diseases, and other liver, muscle, and central nervous system disorders. Beam Therapeutics has formed strategic alliances and research collaborations with leading organizations in the biotechnology and pharmaceutical sectors to advance its innovative therapies.
